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Abstract
Major  progress  for  the  management  of  invasive  as-
pergillosis has come from the introduction of new an-
tifungals since the late 1990s. Although  mortality of
invasive aspergillosis remains as high as 30-50%. Back-
bone of management are prophylaxis, early diagnosis
and early initiation of antifungals for reduction of in-
vasive aspergillosis related mortality. Randomized trials
have been undertaken for the prophylaxis as well as
treatment  of  invasive  aspergillosis  in  the  last  two
decades. Posaconazole is recommended for prophylax-
is  against  aspergillosis  in  patients  treated  for  acute
myelogenous  leukemia,  myelodysplastic  syndrome  or
patients with graft versus host disease after allogeneic
transplantation.  Efficacy has been shown for first-line
therapy of invasive aspergillosis with voriconazole and
liposomal amphotericin B. gastrointestinal resorption
for  the  azoles  posaconazole,  voriconazole  and  itra-
conazole differ considerably. while oral voriconazole
resportion  is  reduced  when  taken  with  food,
posaconazole has to be taken with fatty food for opti-
mal  intestinal  resorption.  Beside  all  advances  in  the
management of invasive aspergillosis important ques-
tions remain unresolved. This article reviews the cur-
rent state of prophylaxis and treatment of invasive as-
pergillosis and points out clinicians unmet needs. 
InTRoducTIon
Fungal infections are an important cause of morbidity
for patients with hematological malignancies. The epi-
demiology of invasive fungal infections has changed
within the last decade. while infections due to candi-
da species continue to be frequent despite a broader
use  of  azoles  in  the  prophylactic  setting,  infections
due  to  Aspergillus  species  remain  the  leading
pathogen in the postmortem epidemiology [1]. The
genus Aspergillus includes over 185 species. out of
these around 20 have been reported causative of op-
portunistic infections in man. The manifestation and
severity of the aspergillosis disease depends upon the
immune status of the patient. Invasive aspergillus in-
fections most commonly affect the lung (see Fig. 1)
and sinuses. other forms of the disease are central
nervous  aspergillosis,  osteomyelitis,  endophthalmitis,
endocarditis  and  disseminated  form  of  aspergillosis
which are attributed with a morbidity and a high risk
of infection related death. Invasive aspergillus infec-
tions  are  rarely  observed  in  healthy  hosts  [2,  3].
Therefore a thorough knowledge of risk factors, po-
tential causative organisms, and the safety and efficacy
of appropriate antifungal agents is required for opti-
mal  management.  Risk  factors  for  aspergillus  infec-
tions are outlined in Table 1 [4, 5]. Infections due to
Aspergillus species are caused in most cases by As-
pergillus  fumigatus,  far  ahead  of  Aspergillus  flavus,
Aspergillus  niger,  Aspergillus  terreus  and  other  As-
pergillus  species  (Table  2).  species  distribution  may
differ which means that local epidemiology should be
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Table 1. Risk Factors for Invasive Aspergillus Infections.
severe and long lasting neutropenia
bone marrow transplantation
acute and chronic graft-versus-host disease
uncontrolled diabetes
continuous use of steroids
uncontrolled construction work
sustainded immune suppression
Fig. 1. Pulmonary aspergillosis with a typical halo sign in the
right lung.
2) Karthaus_Umbruchvorlage  23.03.11  12:09  Seite 145kept in mind (e.g. A. terreus with a lack of susceptibil-
ity  against  amphotericin  B).  definitive  diagnosis  by
culture may take four or more days. Most patients are
treated prior to proven diagnosis.  A delay or inappro-
priate  treatment have been associated with an inverse
outcome of invasive aspergillosis. Early diagnosis of
invasive fungal infection remains a challenge and is of
utmost  importance.  The  detection  of  serum  galac-
tomannan (gM) antigen allows 5-8 days earlier diag-
nosis of invasive aspergillosis when compared to clin-
ical  signs,  imaging  or  even  cultures  of  Aspergillus
species  alone  [6].  Platelia  gM  Aspergillus  EIA  is  a
commercially available test kit that detects an exoanti-
gen of Aspergillus with a high sensitivity and speci-
ficity of > 80% and 90% respectively which may trig-
ger an early treatment initiation against invasive as-
pergillosis. given the high mortality associated with
invasive  aspergillosis  prophylaxis  of  invasive  fungal
infections would be ideal [7]. Antifungal therapy is as-
sociated with adverse events and has a substantial eco-
nomic burden in addition. These aspects must be tak-
en into account. The numbers needed to prevent an
invasive aspergillosis differ considerably between in-
stitutions. Environmental situations are only one rea-
son, beside patients and their risk factors for invasive
aspergillosis. Early preemptive treatment with a safe
antifungal agent would be an alternative approach, if
early diagnosis and effective treatment could reliably
be established. 
AnTIFungAl dRugs
Polyenes were introduced for antifungal treatment in
the late 1950s. Amphotericin B desoxycholate (AmB) is
proven to be effective but toxic. AmB has a lot of se-
vere adverse events including nephrotoxicity and infu-
sion related side effects. Although prolongation of in-
fusion time from two to four and up to 24 h has been
shown  to  be  less  toxic  [8],  recent  guidelines  have
dumped amphotericin B desoxycholate for prophylaxis
and empirical treatment [9, 10]. Three lipid based am-
photericin B formulations have been introduced since
the  1990s.  out  of  these,  liposomal  amphotericin  B
(lAmB) has proved to overcome a substantial number
of adverse events. lAmB is significantly less nephro-
toxic  and  associated  with  fewer  infusion-related  side
effects. Randomized trials with lAmB have shown ef-
ficacy comparable with amphotericin B desoxycholate
for empirical antifungal therapy in patients with febrile
neutropenia  refractory  to  broad-spectrum  antibiotics
[11, 12]. new azoles were introduced with susceptibili-
ty against Aspergillus species. These second generation
azoles have been studied for prophylaxis and treatment
since  the  late  1990s.  voriconazole  and  posaconazole
proved efficacy. voriconazole is approved for 1st-line
treatment of invasive aspergillosis, while posaconazole
is approved for prophylaxis of invasive fungal infec-
tions and 2nd-line treatment of invasive aspergillosis. 
Echinocandins  are  a  new  class  of  antifungals.
Echinocandins  inhibit  the  synthesis  of  1,3-b-d-glu-
can, an essential component of the fungal cell wall.
They exhibit potent in vitro and in vivo antifungal ac-
tivity against candida and Aspergillus species. caspo-
fungin,  Micafungin  and  Anidulafungin  are  approved
for antifungal treatment in the Eu. There was no sub-
stantial difference in efficacy with liposomal ampho-
tericin B in comparison with caspofungin in a random-
ized  trial  for  treatment  of  febrile  neutropenia  [13].
nephrotoxicity and adverse events were observed less
frequent in patients treated with caspofungin. with the
introduction of these new and safer antifungals with a
proven  efficacy  against  aspergillosis  prophylaxis  has
become a major issue and reasonable field for clinical
investigation.
cuRREnT oPTIons FoR PRoPHylAxIs oF
InvAsIvE AsPERgIllosIs
Fluconazole was introduced for prophylaxis of inva-
sive fungal infections in the early 1990s. Two random-
ized, placebo-controlled trials showed that fluconazole
(400  mg/d)  administered  prophylactically  decreased
the  incidence  of  candidiasis  in  blood  and  marrow
transplant  (BMT)  recipients  [14,  15].  In  allogeneic
bone marrow transplant (BMT) recipients the use of
fluconazole (400 mg/d) administered over a period of
75 days following BMT resulted in a decreased rate of
gut graft versus host disease (gvHd) and a persistent
protection  against  disseminated  candida  infections
and candidiasis-related death in addition to an overall
survival  benefit  [16].    Fluconazole  has  major  draw-
backs  due  to  a  growing  emergence  of  non-albicans
species  with  reduced  fluconazole  susceptibility  and
what  is  more  important  a  lack  of  efficacy  against
moulds  as  Aspergillus  species.  Targeted  prophylaxis
against aspergillosis is therefore a need and can not be
covered by fluconazole.
Two randomized controlled trials evaluated the pro-
phylactic use of posaconazole in acute leukemia and in
the  allogeneic  hematopoietic  stem  cell  transplant
(HscT) setting [17, 18]. A total of 304 patients with
acute myelogenous leukemia (AMl) or myelodysplas-
tic syndrome (Mds) that had a chemotherapy-associ-
ated neutropenia were treated in a randomized, multi-
center  study  comparing  posaconazole  (3x200  mg/d)
with  fluconazole  (1x400  mg)  or  itraconazole  (2x200
mg) as antifungal prophylaxis. Primary endpoint was
the incidence of proven or probable invasive fungal
infections during treatment. Proven or probable inva-
sive fungal infections were reported in 7 patients (2%)
in the posaconazole group and 25 patients (8%) in the
fluconazole or itraconazole group (P<0.001). signifi-
cantly fewer patients in the posaconazole group had
invasive aspergillosis (2 [1%] vs. 20 [7%], P<0.001). In
a second trial, oral posaconazole was compared with
fluconazole p.o. for prophylaxis in patients with graft-
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Table 2. Important causative Aspergillus species with oppor-
tunistic Infections in Human.
Aspergillus fumigatus
Aspergillus flavus
Aspergillus niger
Aspergillus nidulans
Aspergillus terreus
Aspergillus versiculor
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was the incidence of proven or probable invasive fun-
gal infections from randomization to day 112 of the
fixed treatment period of the study. In the posacona-
zole  group  were  fewer  breakthrough  invasive  fungal
infections (2.4% vs. 7.6%, P=0.004), particularly inva-
sive aspergillosis (1.0% vs. 5.9%, P=0.001). Although
overall  mortality  was  similar  in  the  two  groups,  the
number of deaths from invasive fungal infections was
reported  lower  under  posaconazole  (1%,  vs.  4%;
P=0.046).  Both posaconazole trials proved to be ef-
fective in the reduction of invasive fungal infections in
particular against aspergillosis. 
Three glucan synthesis inhibitors were studied for
prophylaxis  and/or  for  treatment  of  invasive  fungal
infections. out of these three echinocandins, micafun-
gin has been studied for prophylaxis in the transplant
setting. In a randomized, double-blind, phase III trial,
882 adult and pediatric patients received 50 mg of mi-
cafungin i.v. (1 mg/kg in pts <50 kg) or 400 mg flu-
conazole (8 mg/kg in pts <50 kg) administered once
daily.  The  overall  efficacy  defined  as  absence  of
proven, probable, or suspected systemic fungal infec-
tion through the end of prophylaxis with micafungin
was superior to fluconazole as during the neutropenic
period after HscT (P=.03) [19]. 
liposomal amphotericin B is a lipid formulation of
amphotericin B with hydrogenated soy phosphatidyl-
choline, distearoylphophatidylglycerol, and cholesterol.
The lipid formulation was developed to obtain a lower
toxicity. lAmB was studied in a randomized, unblind-
ed  trial  comparing  intravenous  lAmB  prophylaxis
with no systemic antifungal prophylaxis during neu-
tropenia (50 mg of lAmB as a 1-h infusion every oth-
er  day)  [20].  Invasive  aspergillosis  occurred  less  fre-
quently in patients receiving lAmB-prophylaxis (P =
0.0057), whereas the reduction of invasive candidiasis
did not reach statistical significance (P = 0.0655). li-
posomal amphotericin has been compared to placebo
by using an inhalative setting (twice a week) in 271 pa-
tients with 407 neutropenic episodes (≥10 days). The
primary  end  point  was  occurrence  of  invasive  pul-
monary  aspergillosis  (IPA).  six  patients  with  lAmB
prophylaxis versus 18 placebo patients of developed
IPA (P=.005) [21]. 
In recent years several attempts have been undertak-
en to prove the efficacy of voriconazole for prophylax-
is of invasive fungal infections in hematology malig-
nancies. studies were done in the transplant and non
transplant setting [22]. In a comparative study with al-
logeneic HscT-recipients the rates of invasive fungal
infections at 6 months were 6.6% in the voriconazole
and 10.6% in the fluconazole arm. There was a trend
towards fewer Aspergillus infections in the voricona-
zole  arm  without  being  superior  to  fluconazole
(p=0.11). In addition overall survival at day +180 was
not  different  between  both  arms  (81%  vs  80%)[23].
Trials so far had not the design to show differences be-
tween voriconazole and fluconazole according to anti-
fungal  prophylaxis  of  invasive  aspergillosis,  because
they didnﾴt compare the same endpoint of treatment.
The  conceivable  value  of  voriconazole  for  break-
through fungal infection after posaconazole prophylax-
is is not yet studied in prospective controlled trials.
Itraconazole  has  been  available  since  the  early
1990s. It was studied extensively in the 1990s for pro-
phylaxis  of  invasive  fungal  infections.  It  has  been
available as oral capsules (since 1992), oral solution in
cyclodextrin (since 1997) and intravenous formulation
(since 1999). Itraconazole is highly lipophilic. Intesti-
nal absorption of itraconazole oral capsules is variable
and unpredictable. oral solution of itraconazole has a
better bioavailability compared to capsules. Most sin-
gle  trials  did  not  prove  efficacy  against  invasive  as-
pergillosis  infections.  Adverse  events,  intestinal  ab-
sorption as well as interactions are a major drawback
of  oral  itraconazole  when  used  for  prophylaxis.  A
meta-analysis showed superiority of itraconazole when
compared  with  fluconazole  in  hematological  malig-
nancies. The incidence of invasive Aspergillus infec-
tions was only reduced in trials using the itraconazole
cyclodextrine solution and not itraconazole capsules.
The overall mortality was not reduced [24].
EvIdEncE BAsEd REcoMMEndATIons FoR
AsPERgIllus PRoPHylAxIs
Infectious disease guidelines recommend prophylaxis
against  aspergillosis  on  data  of  randomized  con-
trolled trials. Posaconazole 600 mg/d is strongly rec-
ommended  in  patients  with  acute  myelogenous
leukemia/myelodysplastic  syndromes  or  undergoing
allogeneic stem cell recipients with graft versus host
disease  for  the  prevention  of  invasive  fungal  infec-
tions and attributable mortality of invasive aspergillo-
sis (level A I). Fluconazole 400 mg/d is recommend-
ed in allogeneic stem cell recipients until development
of graft versus host disease only (level A I). Aero  -
solized  liposomal  amphotericin  B  is  recommended
during prolonged neutropenia (level B II). There is
moderate evidence of voriconazole for prophylaxis of
invasive  fungal  infections  measured  and  compared
eighty days after end of prophylaxis [25]. 
Physicians are now headed with the management of
suspected fungal infections in febrile neutropenic pa-
tients  undergoing  posaconazole  prophylaxis.  Posa  -
conazole prophylaxis failure was rare in the trials that
led to the approval of posaconazole. Fever refractory
to  antibiotics  despite  posaconazole  prophylaxis  re-
mains a common clinical scenario during the course of
leukemia treatment however. wait and see or change
of antifungal treatment is the question [26]. IFI under
posaconazole prophylaxis were diagnosed in 2% and
5% of patients with AMl and allogeneic HscT-recipi-
ents with gvHd, respectively. A posaconazole trough
threshold of 0.5 ﾵg/ml has been proposed for opti-
mized  antifungal  prevention.  statistically  different
posaconazole  plasma  concentrations  have  been  ob-
served under various conditions. There is a matter of
debate what is clinically relevant [27]. Thus, drug mon-
itoring of triazole serum concentrations may become
important to minimize toxicity and ensure efficacy [28,
29, 30]. Kohl et al elucidated factors influencing the
pharmacokinetics  of  posaconazole  administered  in
HscT-recipients for prophylaxis. Among the covari-
ates tested, significant effects were found for age (de-
crease in the volume of distribution of 123 liters per
year of age) and the presence of diarrhea (59% loss of
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posaconazole concentrations in allogeneic scT recipi-
ents with hematological malignancies is provided for a
given dose. corresponding adjustments of the starting
dose according to the presence of diarrhea, and ac-
cording to age appear to be justified [31]. 
A  French  trial  retrospectively  analyzed  low
posaconazole plasma concentrations (PPc) defined as
a concentration lower than 500 ng/ml. Fifty-four pa-
tients  were  included:  36  receiving  prophylactic  (200
mg three times a day) and 18 receiving curative (400
mg twice a day) doses of posaconazole. The preva-
lence of low PPcs was 44% (16/36) in the prophylax-
is  group  and  22%  (4/18)  in  the  curative-treatment
group. In the prophylaxis group, low PPcs tended to
be more frequent in cases of digestive disease (62.5%
versus 30%; P = 0.051) and were significantly more
frequent among patients with diarrhea (71.4% versus
27%; P = 0.009) or mucositis (100% versus 33%; P =
0.004).  In  the  curative-treatment  group,  low  PPcs
were significantly more frequent in cases of diarrhea
(75% versus 7%; P = 0.018) [32]. Taken together the
results  of  these  two  trials  suggest  that  therapeutic
drug monitoring of posaconazole is mandatory in im-
munosuppressed patients, at least in those with gas-
trointestinal disorders and the administration of pro-
ton  pump  inhibitors.  Patients  with  fever  during
posaconazole prophylaxis might be switched to an in-
travenous broad spectrum antimycotic, at least in cases
of mucositis and diarrhea. Breakthrough fungal infec-
tions caused by zygomycosis should be taken into ac-
count,  in  particular  for  those  patients  receiving
voriconazole for prophylaxis [33]. case reports with
proven pneumonia due to Rhizopus after long stand-
ing  posaconazole  prophylaxis  have  also  been  pub-
lished  recently  [34].  Fasting  serum  levels  were  in  a
range of 691-904 ng/ml in one of the cases [35]. The
presented  cases  had  severe  graft-versus-host  disease
after  allogeneic  stem  cell  transplantation  associated
with an impaired intestinal absorption of posacona-
zole. 
MAnAgEMEnT oF InvAsIvE AsPERgIllosIs
Patients at highest risk are those with hematological
malignancies and severe neutropenia. Emerging data
have  shown  that  solid  organ  transplant  recipients,
chronic obstructive pulmonary disease and patients in
the intensive care unit receiving steroids might have a
risk  for  invasive  aspergillosis  too.  non-neutropenic,
non-hematological  patients  now  account  for  up  to
40% of all those with invasive aspergillosis. For these
latter patients there is less knowledge of the manage-
ment. The approaches that have been proven to be ef-
fective  in  the  neutropenic  host  may  also  benefit  in
these  patient  groups.  Early  and  effective  treatment
with maximum tolerable dosages of antifungal agents
is the backbone of treatment. 
For  decades  Amphotericin  B  desoxycholate  has
been the only option for invasive aspergillosis until the
early  1990s.  The  introduction  of  voriconazole  has
been a major progress. voriconazole has a broad anti-
fungal efficacy, including Aspergillus species. Patients
with definitive or probable invasive aspergillosis were
studied  in  an  open  randomized  trial  that  compared
voriconazole (2x6 mg/kg on day 1 and 2x4 mg/kg/d
for seven days i.v. followed by p.o treatment) with am-
photericin B desoxycholate (1-1,5 mg/kg/d). At week
12 response was observed in 52.8% in the voricona-
zole and 31.6% in the amphotericin B group. Patients
in  the  voriconazole  arm  had  a  significant  improved
survival  at  week  12  (70.8%  vs  57.9%).  Toxicity  was
lower for patients receiving voriconazole beside visual
disturbances  [36].  since  that  trial  voriconazole  has
been adopted gold standard for the treatment of inva-
sive Aspergillosis. one might argue that amphotericin
B desoxycholat may not have been the optimal com-
petitor, since amphotericin B could be administered a
median of 10 days only [37]. Amphotericin B desoxy-
cholate was the only approved drug for first-line treat-
ment  at  that  time  the  trial  was  designed,  however.
Treatment  with  voriconazole  proved  to  be  effective
even in patients with disseminated aspergillosis infec-
tions.  Moreover,  voriconazole  penetrates  the  central
nervous  system  (cns).  Patients  with  invasive  as-
pergillosis of the cns are known to have a very bad
prognosis  with  a  mortality  of  90%.  voriconazole
showed superior efficacy and survival with a response
in  35%  of  patients  (survival  31%)  [38].  Although
voriconazole is well absorbed from the gut there has
been  reported  a  large  inter-individual  variability  in
voriconazole through blood levels. voriconazole blood
levels  of  >1  mg/l  are  considered  a  minimum  in-
hibitory concentration. lack of response has been ob-
served in patients with voriconazole levels <1 mg/l
[39, 40]. Efficacy against invasive fungal infections was
documented after increasing the voriconazole dosage.
Therefore, therapeutic drug monitoring of voricona-
zole is recommended in particular for those patients
not  responding  under  oral  voriconazole  treatment.
Higher voriconazole levels (> 5.5 mg/l) in contrast
are associated with increased adverse events, in partic-
ular encephalopathy due to voriconazole. co-medica-
tion  with  omeprazole  has  been  observed  with
voriconazole accumulation. In these cases discontinua-
tion of therapy resulted in complete neurological re-
covery.
lIPosoMAl AMPHoTERIcIn B
Treatment  of  invasive  aspergillosis  needs  maximum
tolerable dosages of antifungal drugs. liposomal am-
photericin  B  achieves  maximum  plasma  levels  at  a
dosage of 10 mg/kg per day. Induction treatment of
proven  or  probable  invasive  aspergillosis  with  high
dose (10 mg/kg) lAmB  was compared in a double-
blind trial. 201 Patients with mold infection were ran-
domized to receive lAmB at either 3 or 10 mg/kg per
day for 14 days, followed by 3 mg/kg per day. The pri-
mary end point was complete or partial response. A
favorable response was achieved in 50% and 46% of
patients in the 3- and 10-mg/kg groups, respectively
(P > .05). survival rates at 12 weeks were 72% and
59% (P > .05). significantly higher rates of nephro-
toxicity and hypokalemia were seen in the high-dose
group. liposomal Amphotericin B has been approved
for  first-line  treatment  of  invasive  fungal  infection
[41].  The  AmBiload  trial  was  not  a  comparison  to
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though response and survival rates were in the range
of voriconazole for first-line therapy of invasive as-
pergillosis. A head to head comparison of both drugs
for efficacy against invasive aspergillosis is lacking. 
EcHInocAndIns FoR THE MAnAgEMEnT oF
InvAsIvE AsPERgIllosIs
Echinocandins are approved for 2nd-line treatment of
invasive  Aspergillosis  being  refractory  or  intolerant
against 1st-line drugs [42]. A small open label Phase II
study (n = 61) evaluated caspofungin as first-line ther-
apy for invasive aspergillosis in hematological diseases
with 85% of patients being neutropenic at enrolment.
At the end of treatment one patient had a complete
and 19 patients a partial response [success rate 33%
(20/61)] with 31 patients (51%) showing disease pro-
gression. The 12-week survival rate was 53% (32/60)
[43]. caspofungin has not been compared to voricona-
zole  for  first-line  treatment  of  invasive  aspergillosis
(see  Table  3).  In  addition,  caspofungin  is  an  active
first-line therapy for candida infections in both, neu-
tropenic and non-neutropenic patients [44, 45].
Micafungin and anidulafungin are also approved for
the treatment of invasive candidiasis with fewer data
in hematological patients [46, 47, 48]. However, both
drugs have not been proven to be effective for first-
line treatment for invasive aspergillosis whereas some
data  are  available  on  micafungin  for  refractory  as-
pergillosis [49].
PosAconAzolE FoR TREATMEnT oF InvAsIvE
AsPERgIllosIs
currently there are no data for the first-line treatment
from  randomized  trials.  The  posaconazole  salvage
study was conducted in patients with refractory or in-
tolerant invasive mycoses [50]. These patients were not
randomized in a controlled clinical trial but were in-
cluded as a prespecified control group in the original
study  plan  using  retrospective  data.  A  data  review
committee of 15 experts in antifungal therapy and 2
radiologists  assessed  posaconazole-treated  subjects
and control subjects in a parallel, blinded manner us-
ing predefined methods to assess evaluability and out-
come.  cases  of  aspergillosis  deemed  evaluable  by  a
blinded  data  review  committee  included  107
posaconazole recipients and 86 control subjects (mod-
ified  intent-to-treat  population).  The  overall  success
rate was 42% for posaconazole recipients and 26% for
control  subjects  (P  =  .006).  The  2nd-line  data  of
posaconazole treatment of IA showed efficacy in pa-
tients failing first-line treatment. These data do not al-
low to estimate efficacy in the first-line treatment of
IA with posaconazole.
ITRAconAzolE FoR InvAsIvE AsPERgIllosIs
Intravenous  itraconazole  circumvents  problems  with
intestinal  absorption.  Intravenous  followed  by  oral
itraconazole has been reported for the treatment of
invasive  aspergillosis  in  a  non-randomized  trial  [51].
An open, international, multicenter trial evaluated the
efficacy and safety of i.v. followed by oral itraconazole
capsules  in  patients  with  invasive  pulmonary  as-
pergillosis. Patients received 200 mg itraconazole by an
iv infusion over 60–90 min every 12 h for the first 2
days. For the following 12 days, 200 mg itraconazole
was administered by iv infusion once daily. oral itra-
conazole  capsules  (200-mg)  were  then  administered
twice daily from weeks 3–14. Median iv itraconazole
was 14 days with mean trough concentrations of itra-
conazole after 2 and 14 days 670 and 850 ng/ml, re-
spectively. A complete or partial response was seen at
the last on-treatment assessment in 15 (48%) of 31 pa-
tients, with 6 (19%) showing stable disease. 
MAnAgEMEnT oF InvAsIvE AsPERgIllosIs
wITH gM-MonIToRIng
since the widespread use of posaconazole for prophy-
laxis in high risk hematological malignancies manage-
ment  of  suspected  invasive  aspergillosis  has  raised
new questions in particular, the definition of break-
through aspergillus infection. Is this refractory fever
under  posaconazole  prophylaxis,  or  fever  under
posaconazole and new lung infiltrates? 
galactomannan  (gM)  screening  has  been  intro-
duced in recent years [52]. we have learned to use this
diagnostic  tool  for  early  detection  of  invasive  as-
pergillosis [53]. These data were obtained prior to the
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Table 3. First-line Treatment of Invasive Aspergillosis: Prospective controlled Trials.
study n= design Treatment MdsT  Response  survival 
(range) (cR+PR) week 12
Herbrecht 277 op, rd AmB desoxycholate 1-1.5 mg/kg  10 (1-84) 31.6% 57.9%
2002 nEJM vori 2x6mg/kg d1 and 2x4 mg/kg d2+ i.v.*  77 (2-84) 52.8% 70.8%
cornely 201 db, rd lAmB 3mg/kg (d1-14)                     14 (1-60) 50% 72%
2007 cId lAmB 10 mg/kg (d1-14) }op3mg/kg d 15+
15 (1-57) 46% 59%
Herbrecht 2010 BMT ** 24 op, sa caspofungin 70mg d1/50 mg d2+ 24  33% 50%
viscoli 2009JAc # 61 op, sa caspofungin 70mg d1/50 mg d 2+ 15 (3-84) 33% 53%
Abbreviations: op = open, rd = randomized, db = double blind, sa = single arm, MdsT =  Median duration of study drug treatment
in days, * a switch to oral voriconazole was allowed after day 7, **allogeneic cohort of patients, # hematological malignancies and au-
tologous transplantation
2) Karthaus_Umbruchvorlage  23.03.11  12:09  Seite 149introduction  of  posaconazole  for  prophylaxis.  The
role of quantitative gM-serum levels in patients under
prophylaxis  with  posaconazole  remains  a  matter  of
debate.  different  clinical  scenarios  may  be  encoun-
tered:  patients  who  develop  new  fever  without  any
new  lung  infiltrates,  patients  with  newly  diagnosed
febrile episodes and new lung infiltrates in the absence
of  a  positive  gM-assay,  and  patients  with  fever
plus/minus new lung infiltrates and a positive serum
gM. Monitoring aspergillosis response to therapy by
conventional clinical, radiological, and microbiological
methods remains challenging, because it includes sub-
jective and nonspecific signs, symptoms of infection,
and interpretation of radiological findings that are nei-
ther standardized nor validated. A decrease of gM in
patients with proven aspergillosis might be helpful for
the interpretation of radiological findings during the
course of the disease. A normalization of gM is not
enough to terminate antifungal treatment.
If failure of posaconazole prophylaxis is suspected,
a thorough clinical investigation is necessary. This in-
cludes control of compliance with oral posaconazole
ingestion, timepoint of administration (Posaconazole
administered at dosages of 600-800 mg/day in divided
doses with food) and signs and symptoms of diarrhea
or gastrointestinal gvHd. determining posaconazole
serum/plasma concentration seems to be helpful but
the assessment of serum levels is not a routine in daily
practice. If fever is the only symptom in a patient with
adequate  posaconazole  serum  levels,  a  wait  and  see
policy is justified.
By contrast, posaconazole prophylaxis may be ter-
minated  in  patients  with  a  worsening  clinical  condi-
tion. In particular breakthrough infections related to
zygomycosis have to be ruled out or should be taken
into  account.  Awareness  of  the  local  epidemiology
may be important [54]. For patients developing new
lung  infiltrates  or  symptoms  of  acute  rhinosinusitis
while  being  on  posaconazole  for  IFI  prophylaxis  a
switch to other licensed antifungals should be consid-
ered. There are no data from clinical trials supporting
the use of voriconazole or an echinocandin in patients
who  develop  fever  under  posaconazole  prophylaxis.
of note, voriconazole and the echinocandins have no
clinical efficacy against zygomycosis. A combination
therapy would be of particular interest, e.g. posacona-
zole plus liposomal amphotericin B or an echinocan-
din.    data  from  controlled  clinical  trials  supporting
this concept may be available by the end of 2011. At
present a change to lipid-based amphotericin B seems
to be reasonable for patients with posaconazole pro-
phylaxis with a worsening clinical condition that is sus-
pected to be related to an invasive aspergillosis. Am-
photericin B has a broader spectrum of activity com-
pared to azoles and echinocandins. Furthermore, am-
photericin B covers most candida species and has ac-
tivity against Trichosporum, Blastomyces, cryptococci
as well as zygomycosis.
coMBInATIon oF AnTIFungAl AgEnTs
AgAInsT InvAsIvE AsPERgIllosIs
combined, simultaneous or sequential antifungal thera-
py are often been considered an appropriate option for
salvage treatment of invasive aspergillosis. Preliminary
data suggest that the combination of azoles or lAmB
and echinocandins may increase activity against refrac-
tory  IA  [55,  56].  Anidulafungin  belongs  to  the
echinocandin  family.  A  randomized  double-blind  pla  -
cebo  controlled  Phase  III  trial  compares  efficacy  of
vori  conazole plus anidulafungin or placebo. This trial
has stopped enrolment. data are suspected in late 2011.
It should be emphasized that antifungal prophylaxis
will remain a standard approach in patients at high risk
for invasive fungal infections while meticulous clinical
judgement  and  treatment  of  febrile  neutropenic
episodes  remain  necessary.  new  aszoles,  lipid  based
amphotericin  and  the  echinocandins  have  improved
the  management  of  invasive  aspergillosis.  Patients
with invasive aspergillosis must closely be monitored.
A  switch  of  the  antifungal  regimen  may  help  to
achieve a better outcome of patients worsening under
posaconazole  prophylaxis.  The  question  which  anti-
fungal should be used has to be answered by well-de-
signed prospective clinical trials.
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